Sangamo BioSciences to Host Conference Call to Discuss Results From Phase 2b Trial of SB-509 in Diabetic Neuropathy
RICHMOND, Calif., Sept. 30, 2011 /PRNewswire/ — Sangamo BioSciences, Inc. (Nasdaq: SGMO) today announced that the company will hold a teleconference and webcast at 8:30 am ET, on Monday, October 3, 2011, to discuss results of the Phase 2b clinical trial (SB-509-901) from its ZFP TherapeuticÃ‚® program to develop SB-509 as a treatment for diabetic neuropathy. A press release summarizing the data from the trial will be issued at 7:00 am ET on Monday prior to this call.
The conference call dial-in numbers are (877) 377-7553 for domestic callers and (678) 894-3968 for international callers. The passcode for the call is 15507481. Participants may access the live webcast via a link on the Sangamo BioSciences website in the Investors section under “Events and Presentations http://investor.sangamo.com/events.cfm. For those unable to listen in at the designated time, a conference call replay will be available for one week following the conference call, from approximately 11:30 am ET on October 3, 2011 to midnight ET on October 10, 2011. The conference call replay numbers for domestic and international callers are (855) 859-2056 and (404) 537-3406 respectively. The conference ID number for the replay is 15507481.
Sangamo BioSciences, Inc. is focused on research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP TherapeuticÃ‚® development program is currently in a Phase 2b clinical trial for evaluation of safety and clinical effect in patients with diabetic neuropathy. Sangamo also has a Phase 1/2 clinical trial and two ongoing Phase 1 clinical trials to evaluate safety and clinical effect of a treatment for HIV/AIDS as well as a Phase 1 trial of a treatment for recurrent glioblastoma multiforme. Other therapeutic development programs are focused on Parkinson’s disease, monogenic diseases, neuropathic pain and nerve regeneration. Sangamo’s core competencies enable the engineering of a class of DNA-binding proteins called zinc finger DNA-binding proteins (ZFPs). By engineering ZFPs that recognize a specific DNA sequence, Sangamo has created ZFP transcription factors (ZFP TFs) that can control gene expression and, consequently, cell function. Sangamo is also developing sequence-specific ZFP Nucleases (ZFNs) for gene modification. Sangamo has established strategic partnerships with companies in non-therapeutic applications of its technology including Dow AgroSciences and Sigma-Aldrich Corporation. For more information about Sangamo, visit the company’s website at www.sangamo.com.
ZFP TherapeuticÃ‚® is a registered trademark of Sangamo BioSciences, Inc.
SOURCE Sangamo BioSciences, Inc.